TG Therapeutics Reports Strong Q4, Added to Indices

TG Therapeutics' (NASDAQ:TGTX) shares surged nearly 18% after the company reported a strong fourth-quarter performance and exceeded revenue expectations, with Q4 2024 revenue reaching $108.2 million and a profit of $23.3 million. The company also provided an optimistic revenue guidance for 2025, projecting $540 million, surpassing analysts' estimates of $534.4 million. This growth is largely driven by its multiple sclerosis treatment, Briumvi, whose sales more than tripled year-over-year. TG Therapeutics has been added to major indices, enhancing investor confidence and visibility, and has announced plans to start a pivotal trial for a subcutaneous version of Briumvi by mid-year. Despite broader market declines, TG Therapeutics' performance has outpaced the biotech industry, and its shares have delivered a substantial return of 247.06% over three years. The company's strategic partnerships and clinical advancements continue to support its strong growth trajectory.